earnings
confidence high
sentiment neutral
materiality 0.70
Ekso Bionics Q2 revenue up 57% to $3.5M; net loss widens to $3.0M
EKSO BIONICS HOLDINGS, INC.
2022-Q2 EPS reported
-$0.59
revenue$6,032,000
- Revenue $3.5M (+57% YoY); EksoHealth $3.2M, EksoWorks $0.2M; 17 EksoNR units booked.
- Net loss $3.0M ($0.23/share) vs $1.3M loss ($0.10) in Q2 2021; gross margin 47% vs 58%.
- Received FDA 510(k) clearance for EksoNR for Multiple Sclerosis indication.
- Cash $31.9M at June 30, 2022, down from $40.4M at Dec 31, 2021.
- Gain on warrant revaluation $1.0M; R&D expense up 30% YoY on next-gen products.